Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

被引:98
作者
Acosta, EP [1 ]
Kakuda, TN [1 ]
Brundage, RC [1 ]
Anderson, PL [1 ]
Fletcher, CV [1 ]
机构
[1] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Acad Hlth Sci Ctr, Minneapolis, MN 55455 USA
关键词
D O I
10.1086/313852
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Many factors are involved in the success or failure of antiretroviral therapy. Recent data suggest that there are significant differences in drug absorption and disposition for the protease inhibitor class of antiretroviral drugs, and relationships between plasma concentrations and their antiviral effect have been described. Consequently, the issue of whether therapeutic drug monitoring should be employed for patients receiving treatment with these drugs has arisen. Several criteria must be met before a drug is considered a candidate for therapeutic drug monitoring. These criteria include pharmacological, clinical, and analytic components. Although not all the necessary criteria have yet been met, some of these components have been defined, and additional data are being generated. However, prospectively designed clinical trials must be completed to determine if monitoring protease inhibitor plasma concentrations provides additional clinical benefit to the patient.
引用
收藏
页码:S151 / S159
页数:9
相关论文
共 50 条
[21]   Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors [J].
Roth, VR ;
Kravcik, S ;
Angel, JB .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) :65-67
[22]   Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors:: genotypic and phenotypic testing [J].
García-Lerma, JG ;
Heneine, W .
JOURNAL OF CLINICAL VIROLOGY, 2001, 21 (03) :197-212
[23]   Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors [J].
Charpentier, C ;
Dwyer, DE ;
Mammano, F ;
Lecossier, D ;
Clavel, F ;
Hance, AJ .
JOURNAL OF VIROLOGY, 2004, 78 (08) :4234-4247
[24]   DESIGN OF TIGHT-BINDING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE INHIBITORS [J].
VACCA, JP .
RETROVIRAL PROTEASES, 1994, 241 :311-334
[25]   Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O [J].
Rodés, B ;
Poveda, E ;
Soriano, V .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (11) :4313-4316
[26]   Resistance mechanism of human immunodeficiency virus type-1 protease to inhibitors: A molecular dynamic approach [J].
Dayer, Mohammad Reza ;
Dayer, Mohammad Saaid .
MOLECULAR BIOLOGY RESEARCH COMMUNICATIONS, 2014, 3 (04) :253-267
[27]   Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance [J].
Swanstrom, R ;
Erona, J .
PHARMACOLOGY & THERAPEUTICS, 2000, 86 (02) :145-170
[28]   Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors [J].
Gruber, A ;
Berlit, J ;
Speth, C ;
Lass-Florl, C ;
Kofler, G ;
Nagl, M ;
Zepelin, MB ;
Dierich, MP ;
Wurzner, R .
IMMUNOBIOLOGY, 1999, 201 (01) :133-144
[29]   Protease inhibitors for the treatment of human immunodeficiency virus infection [J].
Kakuda, TN ;
Struble, KA ;
Piscitelli, SC .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (03) :233-254
[30]   Human immunodeficiency virus protease inhibitors and Pneumocystis carinii [J].
Atzori, C ;
Cargnel, A .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (11) :1692-1693